An 11-year-old girl with cancer died after her tumour was treated with an antibiotic in a hospital in Thailand.
An anonymous donor has been honoured for their generosity and the hospital has said it is “extremely thankful”.
A girl named Aneesa was diagnosed with pancreatic cancer in September 2016, after a routine scan showed her tumours were growing.
“I wanted to be the last one in line, but when we were finally given the choice of the operation or the chemotherapy, I chose the chemotherapy,” she told Al Jazeera.
“The doctor told me that the tumours will grow.
I asked him, ‘What will you do about it?’ and he told me, ‘I will give you this medication and I will do it.'”
The girl’s mother said she was given a “tough choice” between chemotherapy and radiation treatments.
“It’s really difficult, because they both had radiation, so they have both gone through the same treatments,” she said.
“But AneESA chose the radiation treatment because she was worried about radiation in the future.”
The hospital said it would also be “extraordinary” if an anonymous donor donated the money needed to treat Aneede, and said they were “extremely grateful”.
“We are very proud to say that this donation has saved Aneesh’s life, and we would like to express our sincere thanks to the anonymous donor for their generous contribution to our hospital,” a statement from the hospital said.
The hospital had previously said it hoped to have an operation in the next couple of weeks, but has not given an exact date.
Aneesa’s parents said they have received messages of support, with one thanking them for their “love and caring”.
“She has become a kind, caring, and beautiful person,” the family wrote on a GoFundMe page set up to help pay for the treatment.
“We are grateful for all of your kind messages.”
Aneesh was the first of several children in Thailand to have cancer treated with a new antibiotic, which was approved in the US in December.
More than 300 people in the country have been treated with the drug, which is used to treat many types of cancer, including the rare genetic disease known as BRCA1 and BRCAs2.
The drug, known as cefotaxime, was first approved by the US Food and Drug Administration in 2015.